文献速递心血管胸部MR

活检证实系统性结节病患者的心血管磁共振预后价值

Prognostic value of cardiovascular magnetic resonance in patients with biopsy-proven systemic sarcoidosis.
PubMed 文献 · Eur Radiol · 2020-03-12

研究纳入114例活检证实的系统性结节病患者,评估临床及心血管磁共振(CMR)参数对复合终点事件的预测价值。中位随访3.1年,34例达复合终点;多因素分析仅左室晚期钆增强(LGE)存在及LGE占左室质量百分比有独立预后价值,LGE阳性组死亡7例(17.5%)vs LGE阴性组2例(2.7%)(p=0.015)。结论认为LGE-CMR心肌强化为结节病危险分层提供独立预后信息,而临床及功能参数缺乏判别力。

要点

  • 左室LGE阳性及LGE占左室质量百分比是结节病患者复合终点事件的独立预测因子(多因素分析均p=0.03)。
  • LGE阳性组死亡7例(17.5%),LGE阴性组死亡2例(2.7%)(p=0.015)。
  • Kaplan-Meier分析显示LGE存在及LGE≥3%可预测无事件生存和患者生存。

关键影像表现/征象

  • 左室射血分数58.2±9.1%,右室射血分数54.7±10.8%。
  • 左室LGE存在于40例(35%),累及5.1%的左室质量(IQR 3.0-12.0%),其中12例(11%)伴右室受累。
  • T2加权成像和/或T2 mapping显示14例存在活动性疾病。

诊断标准与关键数值

  • 复合终点事件共34例;LGE阳性组死亡7例(17.5%),LGE阴性组死亡2例(2.7%)(p=0.015)。
  • 单因素分析中,右室射血分数(p=0.009)、肺动脉压(p=0.002)、LGE存在(p<0.001)及LGE占左室百分比(p<0.001)显著。
  • 多因素分析中,仅LGE存在及LGE占左室百分比显著(均p=0.03)。
  • Kaplan-Meier分析显示LGE存在及LGE≥3%可预测无事件生存和患者生存。
  • 活动性与非活动性疾病患者生存无差异。

临床应用与阅片要点

  • 在结节病患者风险分层中,应关注LGE-CMR是否存在心肌强化及LGE占左室质量百分比。
  • LGE≥3%提示预后不良,可作为风险分层的参考阈值。
  • 临床及功能心脏参数(如射血分数、肺动脉压)对预后判别力有限,报告时需结合LGE结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: As prognosis in sarcoidosis is determined by cardiac involvement, the objective was to study the added value of cardiovascular magnetic resonance (CMR) in risk stratification.

METHODS: In 114 patients (48 ± 12 years/52% male) with biopsy-proven sarcoidosis, we studied the value of clinical and CMR-derived parameters to predict future events, using sustained ventricular tachycardia, ventricular fibrillation, aborted cardiac death, implantable cardioverter-defibrillator (ICD) placement with appropriate shocks, hospitalization for heart failure, and death as composite endpoint. Median follow-up after CMR was 3.1 years (1.1-5.7 years).

RESULTS: The ejection fraction (EF) was 58.2 ± 9.1% and 54.7 ± 10.8% for left ventricle (LV) and right ventricle (RV), respectively. LV late gadolinium enhancement (LGE) was present in 40 patients (35%) involving 5.1% of the LV mass (IQR, 3.0-12.0%), with concomitant RV involvement in 12 patients (11%). T2-weighting imaging and/or T2 mapping showed active disease in 14 patients. The composite endpoint was reached in 34 patients, with 7 deaths in the LGE-positive group (17.5%), versus two deaths in the LGE-negative group (2.7%) (p = 0.015). At univariate analysis, RVEF (p = 0.009), pulmonary arterial pressure (p = 0.002), and presence of LGE (p < 0.001) and LGE (% of LV) (p < 0.001) were significant. At multivariate analysis, only presence of LGE and LGE (% of LV) was significant (both p = 0.03). At Kaplan-Meier, presence of LGE and an LGE of 3% predicted event-free survival and patient survival. We found no difference in active versus inactive disease with regard to patient survival.

CONCLUSION: Myocardial enhancement at LGE-CMR adds independent prognostic value in risk stratification sarcoidosis patients. In contrast, clinical as well as functional cardiac parameters lack discriminative power.

KEY POINTS: • Sarcoidosis often affects the heart. • Comprehensive CMR, including T2 imaging and LGE enhancement CMR, allows to depict both active and inactive myocardial damage. • Patient prognosis in sarcoidosis is determined by the presence and severity of myocardial involvement at LGE CMR.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Flamée L, Symons R, Degtiarova G, et al. Prognostic value of cardiovascular magnetic resonance in patients with biopsy-proven systemic sarcoidosis. Eur Radiol. 2020. PMID: 32166494. doi:10.1007/s00330-020-06765-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。